PCSK9 Inhibitor

In two early clinical studies, the first version of an oral PCSK9 inhibitor was well tolerated and effective for reducing LDL, according to phase 1 data reported at the American Heart Association Scientific Sessions.

In a subgroup analysis of MASTER-DAPT, regardless of whether patients had a history of MI, 1-month DAPT after PCI was noninferior to 3-month or longer DAPT for ischemic events and conferred a reduction in bleeding events.

In a cost-effectiveness model, the PCSK9 inhibitor alirocumab had good economic value at its present cost in patients with a baseline LDL greater than 100 mg/dL, though less value in patients with LDL less than 100 mg/dL.